ACTA MEDICA, Vol 59 No 1 (2016), 22–25
Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s Disease
Xavier Vandemergel, Frédéric Vandergheynst
DOI: https://doi.org/10.14712/18059694.2016.51
zveřejněno: 30. 04. 2016
Abstract
Still’s disease is an inflammatory disorder of unknown etiology. First-line therapy is based on corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) but the frequency of relapses and corticosteroid-induced adverse events are limiting factors. The efficacy of intravenous tocilizumab (TCZ) has been shown at a dose of 8 mg/kg but the corticosteroid-sparing effect of intravenous low-dose TCZ followed by subcutaneous (SC) injection in the course of the disease has been poorly investigated. We report the case of a 28-year old Caucasian woman presenting a relapse of Still’s disease eleven months after diagnosis under treatment with 6 mg of methylprednisolone. TCZ at a dose of 4 mg/kg every 2 weeks was combined with 32 mg of methylprednisolone, followed by 162 mg SC every 3 weeks. Evolution was rapidly favourable with a decrease in corticosteroid doses. We reviewed previously published cases.
klíčová slova: Still’s disease; Tocilizumab; Relapse
Efficacy of Low-Dose Tocilizumab on a Relapse of Adult-Onset Still’s Disease is licensed under a Creative Commons Attribution 4.0 International License.
210 x 297 mm
vychází: 4 x ročně
cena tištěného čísla: 150 Kč
ISSN: 1211-4286
E-ISSN: 1805-9694